丁丙诺啡对HIV病毒抑制的影响
该研究基于约翰霍普金斯HIV临床队列,纳入2002至2017年间启动丁丙诺啡的279名HIV感染者,采用泊松回归和既往事件率比方法评估丁丙诺啡启动对病毒抑制的影响。结果显示,启动丁丙诺啡后病毒抑制(<200拷贝/mL)的患病率增加,且在控制可测量和不可测量混杂因素后,无论基线是否接受抗逆转录病毒治疗,病毒抑制均得到改善。
要点
- 启动丁丙诺啡与HIV病毒抑制(<200拷贝/mL)的患病率增加相关。
- 在控制混杂因素后,丁丙诺啡对基线未接受ART者的病毒抑制效应更明显。
- 阿片类物质使用障碍的HIV感染者应启动丁丙诺啡以改善病毒抑制。
核心结论
- 启动丁丙诺啡可提高HIV感染者病毒抑制的概率,且该效应在控制可测量和不可测量混杂因素后仍存在。
研究设计与样本
- 研究为队列研究,从约翰霍普金斯HIV临床队列中识别2002至2017年间启动丁丙诺啡的279名HIV感染者。
- 采用泊松回归(稳健方差)估计病毒抑制(<200拷贝/mL)的患病率,并使用既往事件率比(PERR)方法匹配对照以控制混杂。
主要发现
- 启动丁丙诺啡后,HIV感染者病毒抑制的患病率比为1.19(95%CI 1.03-1.37)。
- 匹配对照并控制混杂后,基线接受ART者病毒抑制的PERR PR为1.08(95%CI 1.00-1.18)。
- 基线未接受ART者病毒抑制的PR为1.31(95%CI 1.10-1.61)。
临床怎么用
- 对于合并阿片类物质使用障碍的HIV感染者,应考虑启动丁丙诺啡以治疗物质使用并提高病毒抑制率。
- 丁丙诺啡启动可作为治疗即预防策略的一部分,以改善HIV结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use is prevalent among people living with human immunodeficiency virus (HIV; PLWH) and adversely affects HIV outcomes. We assessed the effect of buprenorphine (BUP) initiation on subsequent HIV viral loads. METHODS: We identified PLWH from the Johns Hopkins HIV Clinical Cohort who initiated BUP between 2002 and 2017. Poisson regression with robust variance was used to estimate the prevalence of viral suppression (<200 copies/mL) before and after BUP initiation. We matched individuals who initiated BUP with controls based on viral load measurement dates and used prior event rate ratio (PERR) methods to estimate the effect of BUP initiation on viral suppression. PERR methods account for unmeasured confounders. RESULTS: We identified 279 PLWH who initiated BUP. After BUP initiation, PLWH were more likely to be virally suppressed (prevalence ratio [PR], 1.19; 95% confidence interval [CI], 1.03-1.37). After matching PLWH who initiated BUP to controls and accounting for measured and unmeasured confounders, BUP initiation increased viral suppression for both those on antiretroviral therapy (ART) at baseline (PERR PR, 1.08; 95% CI, 1.00-1.18) and those not on ART at baseline (PR, 1.31; 95% CI, 1.10-1.61). CONCLUSIONS: Our results indicate that the initiation of BUP results in an increase in the probability of being virally suppressed after accounting for both measured and unmeasured confounders. Persons with opioid use disorder should initiate BUP to not only treat substance use but also to increase viral suppression allowing for treatment as prevention.
引用
- Kim J, Lesko CR, Fojo AT, et al. The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression. Clin Infect Dis. 2021. PMID: 34171087. doi:10.1093/cid/ciab578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。